Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

Phase 1 Completed 27 enrolled Shattuck Labs, Inc.

NaSequentialOpen-labelTreatment

Summary

This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer.

Timeline

Start: 2020-06-29
Primary completion: 2023-02-02
Completion: 2023-02-02

Publications

Lakhani NJ, Stewart D, Richardson DL, Dockery LE, Van Le L, Call J, Rangwala F, Wang G, Ma B, Metenou S, Huguet J, Offman E, Pandite L, Hamilton E. First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11;13(1):e010565. doi: 10.1136/jitc-2024-010565.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SL-172154	Protein / enzyme biologic	0.1 mg/kg	Intravenous
Subject	SL-172154	Protein / enzyme biologic	0.3 mg/kg	Intravenous
Subject	SL-172154	Protein / enzyme biologic	1 mg/kg	Intravenous
Subject	SL-172154	Protein / enzyme biologic	3 mg/kg	Intravenous
Subject	SL-172154	Protein / enzyme biologic	10 mg/kg	Intravenous

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications